Chemexpress(SH:688131) Shang Hai Zheng Quan Bao·2025-11-12 18:47Core Points - The company Shanghai Haoyuan Pharmaceutical Co., Ltd. has announced that its convertible bond "Haoyuan Convertible Bond" is expected to meet the redemption conditions due to the stock price performance [2][15]. Summary by Sections Convertible Bond Issuance Overview - The company issued 8.2235 million convertible bonds with a face value of RMB 100 each, totaling RMB 82.235 million, with a term of 6 years [2]. - The bonds were approved by the China Securities Regulatory Commission and listed on the Shanghai Stock Exchange on December 19, 2024 [3]. Convertible Bond Conversion Period - The bonds can be converted into shares from June 4, 2025, to November 27, 2030, with an initial conversion price of RMB 40.73 per share [4]. Conversion Price Adjustments - The conversion price has been adjusted multiple times due to various corporate actions, with the latest adjustment setting the conversion price at RMB 40.47 per share as of October 22, 2025 [8][9]. Redemption Terms and Conditions - The company has outlined redemption terms, including a mandatory redemption at 113% of the face value upon maturity and conditional redemption if certain stock price thresholds are met [10][11]. - The conditional redemption can occur if the stock price remains above 130% of the conversion price for a specified number of trading days [11][15]. Current Stock Performance - As of the announcement date, the company's stock has closed above the conversion price threshold for 10 trading days, indicating a potential trigger for the conditional redemption clause [2][15].